OncoMatch/Clinical Trials/NCT05762900

Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients

Is NCT05762900 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for breast cancer.

Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesNCT05762900Data as of May 2026

This is a phase II study to investigate the feasibility of Ultra-hypofractionated radiotherapy with or without simultaneous integrated boost for low risk breast cancer patients who have received breast conservative surgery of mastectomy.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Disease stage

Required: Stage YPT0-2N0-1, PT0-2N0-1

Stage ypT0-2N0-1 (if receive neoadjuvant therapy) or stage pT0-2N0-1 (if receive upfront surgery)

Prior therapy

Cannot have received: radiation therapy

Lab requirements

Blood counts

hemoglobin ≥100g/l, leukocyte ≥2×109/l, neutrophil ≥1×109/l, platelet ≥80×109/l

Kidney function

creatinine 1.5 mg/dl or less

Liver function

alanine aminotransferase/aspartate aminotransferase ≤2.5×unl

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify